From Dr EvH, regarding my email asking about the
Post# of 36566
(Total Views: 454)
Posted On: 07/20/2020 7:41:29 PM
From Dr EvH, regarding my email asking about the “complete vaccine”. I did hear from Rich Purcell first, but I thought this response was more clear for us laymen.
I realize they kind of spelled this out a bit for us in the PR today as well, but I wanted everyone see this response and also to know he had responded.
—————
Happy to respond to your questions. The main point is that traditional vaccines which lack Ii-Key activation of CD4+ T cells may only last a few months, similar to what people are now reporting may be the extent of immunity in those who have actually been exposed to the virus. We do plan on using two doses given a few weeks apart in what’s called a ‘prime-boost’ regimen. Perhaps this is the cause for confusion. In a variety of studies we’ve seen that it simply works better this way and there are sound immunological reasons for this. But in regards to the longevity of the response, we’ve seen from prior studies of Ii-Key hybrids for other indications that immunity can last for as long as three years after the last dose of Ii-Key. In short, the robustness and longevity of the response is what sets our vaccine technology apart.
Best regards,
Eric
I realize they kind of spelled this out a bit for us in the PR today as well, but I wanted everyone see this response and also to know he had responded.
—————
Happy to respond to your questions. The main point is that traditional vaccines which lack Ii-Key activation of CD4+ T cells may only last a few months, similar to what people are now reporting may be the extent of immunity in those who have actually been exposed to the virus. We do plan on using two doses given a few weeks apart in what’s called a ‘prime-boost’ regimen. Perhaps this is the cause for confusion. In a variety of studies we’ve seen that it simply works better this way and there are sound immunological reasons for this. But in regards to the longevity of the response, we’ve seen from prior studies of Ii-Key hybrids for other indications that immunity can last for as long as three years after the last dose of Ii-Key. In short, the robustness and longevity of the response is what sets our vaccine technology apart.
Best regards,
Eric
(7)
(0)